4.8 Article

Amyotrophic lateral sclerosis

期刊

LANCET
卷 377, 期 9769, 页码 942-955

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(10)61156-7

关键词

-

资金

  1. Sanofi-Aventis
  2. Serono Pharmaceuticals
  3. Merck Sorono
  4. National Health and Medical Research Council of Australia [510233, 568743]
  5. Motor Neurone Disease Research Institute
  6. Irish Health Research Board
  7. American ALS Association
  8. Irish Motor Neurone Disease Research Foundation
  9. Medical Research Council
  10. Clive and Vera Ramacciotti grant
  11. Charles Viertel grant
  12. Merck Serono Australia
  13. Novartis Australia
  14. Medical Research Council [G0701923] Funding Source: researchfish
  15. MRC [G0701923] Funding Source: UKRI

向作者/读者索取更多资源

Amyotrophic lateral sclerosis (ALS) is an idiopathic, fatal neurodegenerative disease of the human motor system. In this Seminar, we summarise current concepts about the origin of the disease, what predisposes patients to develop the disorder, and discuss why all cases of ALS are not the same. In the 150 years since Charcot originally described ALS, painfully slow progress has been made towards answering these questions. We focus on what is known about ALS and where research is heading-from the small steps of extending longevity, improving therapies, undertaking clinical trials, and compiling population registries to the overarching goals of establishing the measures that guard against onset and finding the triggers for this neurodegenerative disorder.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据